Intravenous (IV) Administration

Sustained Protection Against Infection1

In a clinical study of IV administration of GAMMAGARD LIQUID treatment in 61 adult and pediatric PI subjects:

There were no cases of validated acute serious bacterial
infections observed

No patients were hospitalized due to validated bacterial infections

There were 4 cases of validated other bacterial infections observed
(1 urinary tract infection, 1 gastroenteritis, 2 otitis media)

  • In the clinical study, 15 side effects in 8 subjects were serious. Of these, 2 episodes of aseptic meningitis in 1 subject was deemed possibly related to infusion of GAMMAGARD LIQUID.1

Demonstrated Tolerability by Patients on IV Administration

(381/400) of the side effects reported in this study
were considered mild (217) to moderate (164). The remaining 5% of the side effects (19/400) were rated severe.1

Mild side effects were defined as transient discomfort that resolves spontaneously or with minimal intervention.1

Moderate side effects were defined as limited impairment of function and resolves spontaneously or with minimal intervention with no sequelae.1

Severe side effects were defined as marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae.1

Please see below for Detailed Important Risk Information.

GAMMAGARD LIQUID is formulated with1:

  • Added Sugars1
  • Added Sodium1
  • Added Preservatives1

  • Stabilized and buffered with glycine1 for those patients in whom additives may be a concern
  • The packaging is not made with natural rubber latex1


To learn more about PI and GAMMAGARD LIQUID IV treatment, you can download the brochure from our Additional Resources page.

Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.


  • Sign up to get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Enroll Now
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers
  • My Infusion Log & Wellness Calendar Stay on top of your treatment and overall wellness by logging your infusions after every treatment, tracking your daily health, and communicating this information to your healthcare team.
    See More Resources

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

Selected Important Safety Information for GAMMAGARD LIQUID
  • GAMMAGARD LIQUID can cause decreased kidney function or kidney failure, blood clots in the heart, brain, lungs or elsewhere in the body. Call your healthcare professional or go to your emergency department right away if you have: Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem. Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
  • Do not take GAMMAGARD LIQUID if you have a known history of a severe allergic reaction to IgG or other blood products.